EcoDrugPlus

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSCHAG00000021722
Gene Symbol: PDGFRB
1 Cross references
198 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSCHAG00000021639
Gene Symbol: PDGFRB
1 Cross references
198 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSCHAG00000009559
Gene Symbol: PARP3
1 Cross references
200 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSCHAG00000014300
Gene Symbol: PORCN
1 Cross references
195 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSCHAG00000021725
Gene Symbol: KCNMA1
3 Cross references
177 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSCHAG00000017906
Gene Symbol: KCNMA1
1 Cross references
244 Possible Orthologues:

Potassium Channel, Subfamily K, Member 2b

Ensembl ID : ENSCHAG00000012231
Gene Symbol: KCNK2B
1 Cross references
214 Possible Orthologues:

Potassium Channel, Subfamily K, Member 3a

Ensembl ID : ENSCHAG00000023836
Gene Symbol: KCNK3A
1 Cross references
205 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSCHAG00000013212
Gene Symbol: KCNJ11
3 Cross references
122 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSCHAG00000020282
Gene Symbol: KCNJ11
3 Cross references
187 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSCHAG00000001841
Gene Symbol: KCNJ2
3 Cross references
197 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSCHAG00000016282
Gene Symbol: KCNJ2
3 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).